Michael Smolinski
Keine laufenden Positionen mehr
Profil
Michael Smolinski served as the Chief Scientific Officer at Athenex, Inc. from 2008 to 2022.
Prior to that, he worked as the Chief Technology Officer at Homecare Homebase LLC.
He holds a doctorate degree from the State University of New York at Buffalo.
Ehemalige bekannte Positionen von Michael Smolinski
| Unternehmen | Position | Ende |
|---|---|---|
| ATHENEXPAR | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2022 |
Homecare Homebase LLC
 Homecare Homebase LLC Packaged SoftwareTechnology Services Homecare Homebase LLC provides enterprise management software to clients in the healthcare industry. It offers cloud-based solutions for data exchange, communications, claims processing, billing, and logistics, as well as systems implementation, training, and technical support services. The company was founded by April K. Anthony in 1999 and is headquartered in Dallas, TX. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Michael Smolinski
| State University of New York at Buffalo | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Homecare Homebase LLC
Homecare Homebase LLC Packaged SoftwareTechnology Services Homecare Homebase LLC provides enterprise management software to clients in the healthcare industry. It offers cloud-based solutions for data exchange, communications, claims processing, billing, and logistics, as well as systems implementation, training, and technical support services. The company was founded by April K. Anthony in 1999 and is headquartered in Dallas, TX. | Technology Services |
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
